Seehra Jasbir 4

What Happened

• Jasbir Seehra, CEO of Keros Therapeutics (KROS), was granted two derivative awards on February 24, 2026 covering a total of 317,000 shares (217,000 + 100,000). Each grant is reported with an acquisition price of $0.00 and is recorded as a derivative award (stock option-style award) rather than an open-market purchase or sale. This is an award of equity-based compensation, not a share sale.

Key Details

• Transaction date: February 24, 2026; filing date: February 26, 2026 (Form 4) — appears timely.
• Reported acquisition price: $0.00 (derivative awards). No immediate cash payment or sale of shares reported.
• Shares owned after transaction: Not specified in the information provided in your prompt.
• Vesting and conditions:
  • Footnote F1 (217,000 shares): Time-based vesting — 1/4 vests on Feb 24, 2027, then the remainder vests in 12 substantially equal quarterly installments thereafter, subject to continued service.
  • Footnote F2 (100,000 shares): Performance-based vesting in 1/4 increments if the closing price equals/exceeds 125%, 150%, 175% and 200% of the exercise price for 30 calendar days between Feb 24, 2026 and Feb 24, 2031, subject to continued service.
• Filing status: Not flagged as late in the provided data.

Context

• These are equity compensation awards (derivatives/options) granted to the CEO — common for executive pay. They do not represent an immediate purchase of shares on the open market nor an immediate sale; vesting and any eventual exercise or sale will determine future ownership and potential insider selling.
• Performance-based tranches mean some shares only vest if specific stock-price hurdles are met for sustained periods; time-based tranches require continued employment.
• For retail investors: awards like this indicate management compensation and potential future dilution if options are exercised, but they are not a direct market endorsement (no cash purchase).